Aprea Therapeutics, Inc. (NASDAQ:APRE) SVP Gregory Alan Korbel sold 32,960 shares of Aprea Therapeutics stock in a transaction on Monday, September 20th. The stock was sold at an average price of $4.97, for a total transaction of $163,811.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of NASDAQ APRE opened at $4.50 on Thursday. The company has a market cap of $95.34 million and a price-to-earnings ratio of -2.00. Aprea Therapeutics, Inc. has a 12 month low of $3.17 and a 12 month high of $30.99. The stock has a 50-day moving average price of $4.36 and a two-hundred day moving average price of $4.69.
Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Thursday, August 12th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). As a group, equities research analysts forecast that Aprea Therapeutics, Inc. will post -1.77 EPS for the current year.
Several large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC grew its holdings in shares of Aprea Therapeutics by 292.9% during the second quarter. Virtu Financial LLC now owns 41,142 shares of the company’s stock worth $201,000 after purchasing an additional 30,671 shares during the last quarter. Morgan Stanley grew its holdings in shares of Aprea Therapeutics by 2.2% during the second quarter. Morgan Stanley now owns 1,019,776 shares of the company’s stock worth $4,975,000 after purchasing an additional 21,649 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Aprea Therapeutics during the second quarter worth about $162,000. PDT Partners LLC bought a new stake in shares of Aprea Therapeutics during the second quarter worth about $606,000. Finally, Royal Bank of Canada grew its holdings in shares of Aprea Therapeutics by 39.4% during the second quarter. Royal Bank of Canada now owns 21,150 shares of the company’s stock worth $104,000 after purchasing an additional 5,977 shares during the last quarter. Institutional investors own 30.73% of the company’s stock.
About Aprea Therapeutics
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers.
Featured Story: Example of operating income, EBIT and EBITDA
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.